GlobeStar Therapeutics Corp
OTC:GSTC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
O
|
Oceaneering International Inc
LSE:0KAN
|
US |
GlobeStar Therapeutics Corp
Other Liabilities
GlobeStar Therapeutics Corp
Other Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
GlobeStar Therapeutics Corp
OTC:GSTC
|
Other Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Liabilities
$32.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
3%
|
CAGR 10-Years
24%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Liabilities
$2.1B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Liabilities
$5.1B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
4%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Liabilities
$3B
|
CAGR 3-Years
41%
|
CAGR 5-Years
36%
|
CAGR 10-Years
51%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Liabilities
$2.2B
|
CAGR 3-Years
47%
|
CAGR 5-Years
24%
|
CAGR 10-Years
11%
|
|
GlobeStar Therapeutics Corp
Glance View
GlobeStar Therapeutics Corp. is a clinical stage biotechnology company, which engages in the manufacture and patented formulation of previously approved drugs for the treatment of Multiple Sclerosis. The company is headquartered in Richland, Washington. The company went IPO on 2011-05-21. The firm is focused on introducing a patented formulation of drugs for the treatment of Multiple Sclerosis and other neurodegenerative diseases. The firm owns the global license from the inventors, who are based in Italy. The firm has acquired license for a patented method of treating neurodegenerative diseases such as Multiple Sclerosis by administering a synergistically effective amount of the composition to an individual suffering from neurodegeneration and treating neurodegeneration. GlobeStar Therapeutics is initiating discussions with the Food and Drug Administration (FDA) on clinical trial design in preparation for FDA submission and approval pathway.
